drugset / Trial / NCT04515147
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
RandomizedSequentialTriple-blindPrevention
Summary
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV.
Timeline
- Start
- 2020-09-21
- Primary completion
- 2022-02-21
- Completion
- 2022-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Havrix | Vaccine | — | Intramuscular |
| Comparator | Prevnar 13 | Vaccine | — | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 6 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 12 ug | Intramuscular |